NSIS B — Novozymes A/S Share Price
0.000.00%
Last trade - 00:00- DKK191.07bn
- DKK202.36bn
- €3.83bn
- 75
- 10
- 70
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.73 | ||
| PEG Ratio (f) | 0.83 | ||
| EPS Growth (f) | 52.57% | ||
| Dividend Yield (f) | 1.56% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.29 | ||
| Price to Tang. Book | 22.23 | ||
| Price to Free Cashflow | 38.79 | ||
| Price to Sales | 6.68 | ||
| EV to EBITDA | 25.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.55% | ||
| Return on Equity | 4.69% | ||
| Operating Margin | 13.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1,880.17 | 2,010.83 | 2,360.16 | 2,402.99 | 3,833.5 | 4,244.08 | 4,626.47 | 14.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -0.06 | +11.38 | +10.07 | +0.95 | -39.01 | +83.81 | +12.64 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Bayer and Syngenta in Agriculture and DSM and Adisseo in Animal Health & Nutrition..
Directors
- Joergen Buhl Rasmussen NEC (67)
- Ester Baiget PRE (51)
- Cees de Jong NVC (60)
- Lars Green CFO (54)
- Graziela dos Santos Malucelli COO (49)
- Claus Fuglsang EVP (54)
- Morten Rasmussen EVP (46)
- Amy Byrick EVP (48)
- Anders Lund EVP (49)
- Tina Sejersgaard Fanoe EVP (53)
- Anne Breum DRC (61)
- Heine Dalsgaard DRC (51)
- Anders Hentze Knudsen DRC (63)
- Kasim Kutay DRC (56)
- Preben Nielsen DRC (56)
- Jens Oebro DRC (45)
- Mathias Uhlen DRC (68)
- Sharon James IND (61)
- Kim Stratton IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 13th, 2000
- Public Since
- May 27th, 1905
- No. of Shareholders
- 100,000
- No. of Employees
- 10,582
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 466,135,789
- Address
- Krogshoejvej 36, BAGSVAERD, 2880
- Web
- https://www.novozymes.com/
- Phone
- +45 44460000
- Contact
- Tobias Bjoerklund
- Auditors
- EY Godkendt Revisionspartnerselskab
Upcoming Events for NSIS B
Q1 2025 Novozymes A/S Trading Statement Release
Novozymes A/S Roadshow - Copenhagen
Novozymes A/S Roadshow - Frankfurt
Novozymes A/S Roadshow - London
Novozymes A/S at Barclays European Leadership Conference
Novozymes A/S at BNP Paribas Exane Consumer Ingredients Conference
Novozymes A/S at Deutsche Bank Global Consumer Conference
Half Year 2025 Novozymes A/S Earnings Release
Similar to NSIS B
Flugger A/S
OMX Nordic Exchange - Copenhagen
Rias A/S
OMX Nordic Exchange - Copenhagen
SP A/S
OMX Nordic Exchange - Copenhagen
FAQ
What is the Novozymes A/S share price?
As of Today at 22:21 UTC, shares in Novozymes A/S are trading at DKK409.90. This share price information is delayed by 15 minutes.
How has the Novozymes A/S share price performed this year?
Shares in Novozymes A/S last closed at DKK409.90 and the price had moved by +7.16% over the past 365 days. In terms of relative price strength the Novozymes A/S share price has outperformed the FTSE Global All Cap Index by +5.28% over the past year.
What are the analyst and broker recommendations for Novozymes A/S?
The overall consensus recommendation for Novozymes A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Novozymes A/S dividend yield?
The Novozymes A/S dividend yield is 1.51% based on the trailing twelve month period.
Does Novozymes A/S pay a dividend?
Last year, Novozymes A/S paid a total dividend of €0.83, and it currently has a trailing dividend yield of 1.51%. We do not have any data on when Novozymes A/S is to next pay dividends.
When does Novozymes A/S next pay dividends?
We do not have data on when Novozymes A/S is to next pay dividends. The historic dividend yield on Novozymes A/S shares is currently 1.51%.
How do I buy Novozymes A/S shares?
To buy shares in Novozymes A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Novozymes A/S?
As of the previous close price of DKK409.90, shares in Novozymes A/S had a market capitalisation of DKK191.07bn.
Where are Novozymes A/S shares listed?
Here are the trading details for Novozymes A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: NSIS B
What kind of share is Novozymes A/S?
Based on an overall assessment of its quality, value and momentum Novozymes A/S is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Novozymes A/S share price forecast for 2025?
The analyst consensus target price for shares in Novozymes A/S is DKK487.94. That is 19.04% above the last closing price of DKK409.90.
Analysts covering Novozymes A/S currently have a consensus Earnings Per Share (EPS) forecast of €1.84 for the next financial year.
Find out moreWhat is the trend in the Novozymes A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novozymes A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -6.94%.
As of the last closing price of DKK409.90, shares in Novozymes A/S were trading -3.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Novozymes A/S PE Ratio?
The Novozymes A/S PE ratio based on its reported earnings over the past 12 months is 28.73. The shares last closed at DKK409.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Novozymes A/S?
Novozymes A/S' management team is headed by:
- Joergen Buhl Rasmussen - NEC
- Ester Baiget - PRE
- Cees de Jong - NVC
- Lars Green - CFO
- Graziela dos Santos Malucelli - COO
- Claus Fuglsang - EVP
- Morten Rasmussen - EVP
- Amy Byrick - EVP
- Anders Lund - EVP
- Tina Sejersgaard Fanoe - EVP
- Anne Breum - DRC
- Heine Dalsgaard - DRC
- Anders Hentze Knudsen - DRC
- Kasim Kutay - DRC
- Preben Nielsen - DRC
- Jens Oebro - DRC
- Mathias Uhlen - DRC
- Sharon James - IND
- Kim Stratton - IND